Abstract
Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial re-sponse, stressing the need for improved strategies. Chemokines, as mediators of immune cell trafficking, play an important role in the composition of the tumor microenvironment and exert both pro-and antitumorigenic functions. Here, chemokines may represent valuable prognostic biomarkers of response to immunotherapy and a strategy to improve immunotherapies. In this review, the pleiotropic functions of chemokines in the tumor microenvironment (TME) and strategies of utilizing chemokines or chemokine antagonism in immunother-apy are discussed. The review highlights preclinical and clinical studies that apply or target chemokines in monotherapy or in combination therapies.
| Dokumententyp: | Zeitschriftenartikel |
|---|---|
| Fakultät: | Medizin |
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
| ISSN: | 2405-8025 |
| Sprache: | Englisch |
| Dokumenten ID: | 115436 |
| Datum der Veröffentlichung auf Open Access LMU: | 02. Apr. 2024, 08:14 |
| Letzte Änderungen: | 02. Apr. 2024, 08:14 |
| DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 452881907 |
- Dokument bearbeiten
